Quizartinib is a potent and selective inhibitor of FLT3 (Kd = 1.6nM, IC50 = 0.56 nM MV4-11 cells).1 It is in clinical trials for treatment of Acute Myelogenous Leukemia (AML).2,3 Quizartinib priming resulted in prevention of myelosuppression in mice treated with 5-FU and Gemcitabine.4 Quizartinib showed significant reversal of ABCG2-mediated multidrug resistance ( 3 µM) via antagonism of drug efflux function.5,6
* VAT and and shipping costs not included. Errors and price changes excepted